sCD163 in PBC Patients - Assessment of Treatment Response
Recruiting
Observational Study
Primary Biliary Cirrhosis
Liver Inflammation
Ursodeoxycholic Acid
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- University of Aarhus · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) is the first line treatment for patients with PBC. However, up to 40% of patients respond inadequate to this treatment.
sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble man…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Newly diagnosed with Primary biliary cholangitis
* No treatment with UDCA
Exclusion Criteria:
* Patient under 18 years
* Expected lifetime under 6 months
* Expected liver transplantation within 6 months
* Liver cancer
* Cirrhosis from other causes
Contacts